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A B S T R A C T
Objectives: To describe all published articles that have conducted
comparisons of model-based effectiveness and cost-effectiveness
results in the ﬁeld of vaccination. Speciﬁc objectives were to 1)
describe the methodologies used and 2) identify the strengths and
limitations of the studies. Methods: We systematically searched
MEDLINE and Embase databases for studies that compared predic-
tions of effectiveness and cost-effectiveness of vaccination of two or
more mathematical models. We categorized studies into two groups
on the basis of their data source for comparison (previously published
results or new simulation results) and performed a qualitative syn-
thesis of study conclusions. Results: We identiﬁed 115 eligible articles
(only 5% generated new simulations from the reviewed models)
examining the effectiveness and cost-effectiveness of vaccination
against 14 pathogens (69% of studies examined human papillomavi-
rus, inﬂuenza, and/or pneumococcal vaccines). The goal of most of
studies was to summarize evidence for vaccination policy decisions,
and cost-effectiveness was the most frequent outcome examined.
Only 33%, 25%, and 3% of studies followed a systematic approach to
identify eligible studies, assessed the quality of studies, and per-
formed a quantitative synthesis of results, respectively. A greater
proportion of model comparisons using published studies followed a
systematic approach to identify eligible studies and to assess their
quality, whereas more studies using new simulations performed
quantitative synthesis of results and identiﬁed drivers of model
conclusions. Most comparative modeling studies concluded that
vaccination was cost-effective. Conclusions: Given the variability in
methods used to conduct/report comparative modeling studies,
guidelines are required to enhance their quality and transparency
and to provide better tools for decision making.
Keywords: comparative modeling studies, effectiveness and cost-
effectiveness, infectious diseases, systematic review of the
literature, vaccination.
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Introduction
Over the past 20 years, there has been a steep rise in the
development of mathematical models predicting the effective-
ness and cost-effectiveness of vaccination to help inform policy
decisions [1]. Several elements have contributed to this rise. First,
despite a considerable decrease in the burden of infectious
diseases over the past decades, infectious diseases still account
for 11.5% of all deaths worldwide (46,000,000 deaths in 2012) [2].
The prevention/control of infectious diseases remains an impor-
tant public health priority due to this burden, combined with
pandemics and frequent outbreaks of emerging diseases. Second,
advances in medicine have contributed to the development of
new vaccines to prevent/control infectious diseases. Vaccination
is potentially one of the most effective interventions at the
population level and has historically been shown to be cost-
effective [3–5]. Nevertheless, the higher price of recent vaccines
has prompted a deeper examination of the effectiveness and
cost-effectiveness of different vaccination strategies by decision
makers [6]. Major funders and decision makers of vaccination
programs such as Gavi The Vaccine Alliance, the Bill & Melinda
Gates Foundation, the World Health Organization Strategic Advi-
sory Group of Experts, as well as national immunization technical
advisory groups in many countries such as the United Kingdom
and the United States now require evidence of public health and
economic impact at the population level before supporting
vaccine introduction [7–12].
Mathematical models provide a formal framework to examine
the effectiveness and cost-effectiveness of different interventions
and to identify those that maximize health in the context of
1098-3015$36.00 – see front matter Copyright & 2018, ISPOR-The Professional Society for Health Economics and Outcomes Research.
Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
https://doi.org/10.1016/j.jval.2018.03.014
* Address correspondence to: Marc Brisson, Centre de recherche du CHU de Québec—Université Laval, Axe Santé des populations et
pratiques optimales en santé, Hôpital Saint-Sacrement, 1050 chemin Ste-Foy, Québec G1S 4L8, Canada.
E-mail: marc.brisson@crchudequebec.ulaval.ca
V A L U E I N H E A L T H 2 1 ( 2 0 1 8 ) 1 2 5 0 – 1 2 5 8
limited budgets [6]. Such models translate information from
randomized clinical trials (i.e., vaccine efﬁcacy at the individual
level calculated over a short period of follow-up) into long-term
predictions of the population-level effectiveness and cost-effec-
tiveness of vaccination. They, however, require many simpliﬁca-
tions and assumptions related to the model design, which may
lead to variability in model predictions and uncertainty for
decision makers [6,13]. There are several recent and ongoing
efforts to standardize mathematical modeling studies [14,15].
Nevertheless, the increasing demand for these types of mathe-
matical models still exceeds available expertise and the quality of
models varies considerably, particularly in the prevention/control
of infectious diseases [6].
Given the rise in the number of modeling studies and
uncertainty, reviews or comparative modeling studies are
increasingly being used to synthesize, compare, and/or under-
stand different models’ predictions of the effectiveness and cost-
effectiveness of an intervention so as to assess model-based
evidence for policy making. More speciﬁcally, these comparative
modeling studies are undertaken to 1) describe the models that
have been used to examine a policy question; 2) better under-
stand the impact of model inputs, assumptions, and parameters
on predictions; 3) characterize the robustness/variability of differ-
ent model predictions to assess their suitability for policy rec-
ommendations; and/or 4) synthesize conclusions from several
models to inform policy recommendations. Although several
recognized guidelines are available for systematic reviews of
epidemiological studies or randomized controlled trials (e.g.,
Preferred Reporting Items for Systematic Reviews and Meta-
Analyses (PRISMA) and Meta-analysis Of Observational Studies
in Epidemiology (MOOSE)) [16,17], there are no such guidelines for
reviews or comparative modeling studies. Consequently, compa-
rative modeling studies vary greatly in the methodology used and
the reporting of methods/results.
The aim of this systematic review was to identify and
describe all published articles that have conducted compari-
sons of model-based effectiveness and cost-effectiveness
results in the ﬁeld of vaccination. Speciﬁc objectives are to 1)
describe the different methodologies used and 2) identify the
strengths and limitations of the comparative modeling studies
identiﬁed.
Methods
Search Strategy and Selection Criteria
We systematically reviewed the global literature and reported it
in accordance with the PRISMA guidelines [16]. Studies were
eligible for inclusion if they fulﬁlled the following criteria: 1) they
compared or reported the results of more than one mathematical
model, 2) the intervention modeled was vaccination, and 3) the
outcome was the population-level effectiveness or cost-effective-
ness/cost-beneﬁt of vaccination. We searched the MEDLINE and
Embase databases in May 2016, with no restriction on the
publication date or language of the publication. We used a
combination of the following Medical Subject Heading terms,
title, or abstract words: (“immunization programs,” “immuniza-
tion,” “vaccination,” “vaccine”) and (“infection,” “infectious dis-
ease,” “communicable disease,” “bacterial infections and
mycoses,” “parasitic diseases,” “virus diseases”) and (“mathemat-
ical model,” “statistical model,” “theoretical model,” “nonlinear
dynamics,” “immunological models,” “disease simulation,” “com-
puter simulation,” “computer model,” “cost-beneﬁt analysis,”
“cost-effectiveness,” “risk-beneﬁt analysis”) and (“comparison,”
“review,” reviewed”). The exact searches for PubMed and Embase
are presented in Appendix Table S1 in Supplemental Materials
found at https://doi.org/10.1016/j.jval.2018.03.014. We identiﬁed
eligible studies by reviewing titles and abstracts, and we also
searched the reference lists of eligible articles. Two reviewers
independently assessed the eligibility of all studies. Any dis-
crepancy between the two investigators was resolved by
discussion.
Data Extraction
Two reviewers used a standardized form (see Appendix Table S2
in Supplemental Materials found at https://doi.org/10.1016/j.jval.
2018.03.014) to independently extract the characteristics of the
comparative modeling studies. Studies were ﬁrst categorized into
two groups on the basis of their source of data for comparison: 1)
comparisons that were based purely on results available in
published articles (previously published results only) and 2)
comparisons that were based on generating new simulations
from the model reviewed that were not previously available in
the published literature (results from new simulations). Then, the
following characteristics were extracted: journal and year of
publication, countries of the models included in each study,
funding source, main objective (to describe model characteristics
and parameter, to summarize/provide predictions and variability
around prediction, or to understand variability in predictions),
pathogen and vaccination strategy examined, procedure used for
study identiﬁcation (systematic review, nonsystematic review, or
convenience sample), number of models included, presence and
description of quality assessment of the studies/models included,
main outcome used for comparison (effectiveness, cost-effective-
ness/cost-beneﬁt, or both), type of results synthesis (qualitative
or quantitative), and main conclusions of the comparative mod-
eling studies stated by the authors. See Appendix Table S2 in
Supplemental Materials for more details on the standardized
form used to extract the characteristics of the comparative
modeling studies.
Data Synthesis
We conducted a qualitative synthesis of the published litera-
ture. Given the great variability in comparative modeling studies
and our main objective to describe all published articles that
have conducted comparisons of model-based effectiveness and
cost-effectiveness/cost-beneﬁt results, statistical heterogeneity
analysis and pooling of data were not relevant. In addition, we
decided a priori to stratify the presentation of results according
to the type of results included in the comparative modeling
study (previously published results only or results from new
simulations). These two approaches are very different and our
aim was to describe and compare their main strengths and
limitations.
Results
In our search, we identiﬁed 1860 potentially relevant articles, of
which 115 met the inclusion criteria (Fig. 1). Most of the com-
parative modeling studies (n ¼ 109) presented a synthesis of
previously published results, whereas only six studies presented
the results obtained from new simulations performed speciﬁcally
for the purposes of the comparative study. As illustrated in
Figure 2A, there was a steep rise in the publication of compara-
tive modeling studies since 2006. This rise is mostly attributable
to the publication of comparative modeling studies of human
papillomavirus (HPV) and inﬂuenza vaccination. The six compa-
rative modeling studies using new simulations were published
between 2010 and 2016 (Fig. 2B).
The main characteristics of the eligible comparative modeling
studies are presented in Table 1. Although some studies were
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restricted to either high-income countries (HICs) or low- and
middle-income countries (LMICs) only, 29% (32 of 109) of studies
using published results and 50% (3 of 6) of studies using new
simulations presented model outcomes representative of both
country income groups [18]. Most of the studies were undertaken
with the overall objective of summarizing existing evidence and
providing predictions for decision makers (93% [101 of 109]
published results/83% [5 of 6] new simulations). Of note, 67%
(4 of 6) of comparative modeling studies using new simulations
also aimed at describing model predictions/characteristics and
understanding variability in predictions. Cost effectiveness/cost-
beneﬁt was the most frequently examined outcome (83% [91 of
109] published results/67% [4 of 6] new simulations). A quantita-
tive synthesis of results was performed by only 1% (1 of 109) of
studies using previously published results and 33% (2 of 6) of
studies using new simulations. HPV, inﬂuenza, and pneumo-
coccus were the three most frequently examined pathogens (69%
[75 of 109] published results/50% [3 of 6] new simulations) and
routine childhood vaccination was the vaccination strategy most
frequently examined (55% [60 of 109] published results/67% [4 of
6] new simulations). Although several guidelines [16,17] recom-
mend the use of a systematic approach to identify all potentially
eligible studies and the assessment of the quality of studies, very
few of the comparative modeling studies followed these recom-
mendations. Only 35% (38 of 109) of studies using previously
published results used a systematic approach to identify eligible
articles and 26% (29 of 109) assessed the quality of studies,
whereas none of the studies using new simulations followed
these recommendations. When the quality of studies included in
the comparative modeling study was assessed, the tool most
frequently used was the Drummond checklist for assessing
economic evaluations or an adaptation of this checklist (11 of
29 studies) [19–21]. Other tools used included the Consolidated
Health Economic Evaluation Reporting Standards (CHEERS) [22]
checklist and the Consensus on Health Economic Criteria list
(CHEC-list) [23] (see Appendix Table S3 in Supplemental Materials
found at https://doi.org/10.1016/j.jval.2018.03.014). These tools may
have been less frequently used because the Drummond checklist
was published in 1997, several years before the other tools.
The main conclusions of model comparisons are presented in
Table 2 (see Appendix Table S4 in Supplemental Materials found
at https://doi.org/10.1016/j.jval.2018.03.014). Of note, the conclu-
sions presented in Table 2 and in Appendix Table S4 in
Supplemental Materials represent the interpretation of the
authors who conducted the comparative modeling studies and
are rarely based on a quantitative pooled estimate of effective-
ness or cost-effectiveness/cost-beneﬁt. For all pathogens (except
dengue), the comparative modeling studies identiﬁed at least one
vaccination strategy that would be cost-effective. The main factor
driving cost-effectiveness is identifying an optimal target pop-
ulation for vaccination: either age group, sex, disease-speciﬁc risk
group, and/or region of the world. For example, the comparative
modeling studies report that HPV vaccination is cost-effective for
girls in HICs and LMICs. Nevertheless, HPV vaccination is not
cost-effective for boys in countries with high vaccination cover-
age among girls. Comparative modeling studies ﬁnd that inﬂu-
enza vaccination is cost-effective for elderly and high-risk groups
in HICs, but results vary for working adults and children in HICs.
The modeling assumptions with the greatest impact on cost-
effectiveness of vaccination identiﬁed by comparative modeling
studies are natural history of diseases, herd effects, and duration
of vaccine protection. For example, the duration of protection of
the herpes zoster vaccine is a key driver of cost-effectiveness
Fig. 2 – Number of comparative modeling studies over time
according to (A) the pathogen examined and (B) the type of
results presented.
Fig. 1 – Study selection.
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Table 1 – Summary of characteristics of the 115 independent reviews included.
Characteristic Published results (n ¼ 109) New simulations (n ¼ 6)
% (n) References % (n) References
General information
Publication date
1992–2000 7% (8) [26–33] 0% (0)
2001–2005 16% (17) [34–50] 0% (0)
2006–2010 26% (28) [51–78] 17% (1) [135]
2011–2015/2016 51% (56) [79–134] 83% (5) [25,136–139]
Country
HIC and LMIC 29% (32) [27–29,34,37,43,47,49,53,57,65,66,70,71,75,79,81,85,86,91,93–99,106,112,116,
125,131]
50% (3) [135,136,138]
HIC only 58% (63) [26,30–33,35,36,38–42,44–46,48,50–52,54–56,58–64,67,69,72–74,77,78,80,84,
87–90,92,100,102–104,108–110,113,115,117–121,123,124,128,129,132,133]
17% (1) [139]
LMIC only 12% (13) [68,76,82,83,101,105,107,114,122,126,127,130,134] 33% (2) [25,137]
Missing 1% (1) [111] 0% (0)
Objectives
Objectives of model comparison
Describe model characteristics/parameters 39% (42) [42,44,45,50,52,54–59,62,64,66–68,74,75,77,78,80,86,88,90,91,94,95,98,103,104,
106,108,111,113,115,117,120,124,126,127,129,130]
67% (4) [135–138]
Summarize/provide predictions and variability 93% (101) [26–49,51–57,59–74,76–85,87–93,95–110,112–126,128,130–134] 83% (5) [25,135,137–139]
Understand variability in predictions 16% (17) [45,52,56,57,59,66,67,74,77,78,80,88,90,95,98,103,125] 67% (4) [135–138]
Intervention
Pathogen examined
Human papillomavirus 25% (27) [52,54,56,58,60,61,67,69,72,77,78,80,84,89,96,100,101,103,114–116,121,126–
128,133]
33% (2) [137,139]
Inﬂuenza virus 23% (25) [26,28,31–33,38,51,53,61,65,70,73,81,85,87,88,91,93,94,100,102,105,106,126,133] 0% (0)
Pneumococcus 21% (23) [30,35,36,40,43,45,48,55,59,62,74,79,83,86,102,111,120,124,126,127,131–133] 17% (1) [135]
Varicella zoster virus (varicella vaccination) 9% (10) [36,42,64,75,100,102,109,123,129,133] 0% (0)
Hepatitis B virus 9% (10) [27,29,34,61,76,100,102,104,126,133] 0% (0)
Rotavirus 9% (10) [49,66,82,83,98,100,125–127,133] 17% (1) [138]
Hepatitis A virus 7% (8) [36,39,41,57,61,100,107,126] 0% (0)
Varicella zoster virus (herpes zoster
vaccination)
6% (6) [71,108,113,117,118,123] 0% (0)
Bordetella pertussis 6% (7) [46,61,63,90,92,95,119] 0% (0)
Neisseria meningitidis 6% (6) [44,47,50,61,100,133] 0% (0)
Measles and rubella viruses 5% (5) [37,99,100,110,127] 17% (1) [136]
Dengue virus 2% (2) [122,134] 0% (0)
Haemophilus inﬂuenza serotype B 1% (1) [68] 0% (0)
Typhoid 1% (1) [130] 0% (0)
Other 5% (5) [97,100,112,126,127] 17% (1) [25]
Vaccination strategy
Routine childhood 55% (60) [27,29,34–37,39,41–47,49,50,55,57,59,61,62,64–66,68,70,75,76,79,81–83,86,91,93,94,
97–100,102,104–107,109,110,112,120,122,123,125–127,129–134]
67% (4) [25,135,136,138]
Routine adolescents 43% (47) [27,29,34,35,37,39,41,42,44,46,52,54,56–58,60,61,67,69,72,76,77,80,84,89,93,94,96,
99–106,109,110,112,114–116,119,121,126–128]
17% (1) [137]
Routine adults 31% (34) [27,29,32,34,35,38,39,44,46,48,57,70,71,74,76,87,88,92–94,99,100,102,104–106,111,
112,119,120,123,124,127,134]
0% (0)
Routine elderly 31% (34) [26–28,30,31,33–35,39,40,43,46,48,53,57,70,71,73,76,85,93,94,100,102,104–106,108,
112,113,117,118,124,127]
0% (0)
Targeted high-risk groups (other than age) 31% (34) [27,29,34,35,37,39,41–43,46,48,51,57,64,76,85,93,94,97,99,100,102,104–107,110,112,
119,122,126,127,130,134]
0% (0)
Other 6% (7) [44,47,50,63,78,90,95] 17% (1) [139]
Methods of the comparative studies
Search strategy/study identiﬁcation
Review 100% (109) 33% (2)
Systematic 35% (38) [30,51,57,61,63,68,71,72,74,76,77,79,83,86,93,94,96,99–102,104,105,108–110,114,
115,117–123,126,132,133]
0% (0)
Nonsystematic 65% (71) [26–29,31–50,52–56,58–60,62,64–67,69,70,73,75,78,80–82,84,85,87–92,95,97,98,103,
106,107,111–113,116,124,125,127–131,134]
33% (2) [137,138]
Convenience sample 0% (0) 67% (4) [25,135,136,139]
Number of modeling studies included
2–10 28% (30) [29,31–33,36,40,44,47,49,52,56,58,71,73,78,87,88,92,103–105,107,111,114,120,122,
124,128,130,134]
100% (6) [25,135–139]
11–20 39% (42) [35,38,41–43,45,46,50,51,53–55,59,62,63,65–70,74,76,77,80–82,85,86,89–91,95,97,
108,110,113,115,117,118,121,129]
0% (0)
421 29% (32) [27,34,37,48,57,60,61,64,72,75,79,84,93,94,96,98–102,106,109,112,116,119,123,
125–127,131–133]
0% (0)
Missing 5% (5) [26,28,30,39,83] 0% (0)
Quality assessment of studies
No 62% (68) [27,29,31–39,41,42,44–48,50–56,58–62,64–67,70,73,75–78,80–82,84,86–92,94,95,
97,98,101,102,105,106,112,113,116,120,124,128,131,132,134]
83% (5) [25,136–139]
Yes 26% (29) [43,49,57,63,68,69,72,74,79,85,93,96,99,100,103,104,107–109,114,117,119,121–123,
126,127,130,133]
0% (0)
Missing 11% (12) [26,28,30,40,71,83,110,111,115,118,125,129] 17% (1) [135]
Main outcome used for comparison
Effectiveness 0% (0) 17% (1) [136]
Cost-effectiveness/cost-beneﬁt 83% (91) [26,27,29,32–37,39–51,56–62,64–68,70,71,73–85,87–93,95–109,111–118,120–129,
131,133]
67% (4) [135,137–139]
Effectiveness and cost effectiveness/cost-
beneﬁt
16% (17) [28,30,31,38,52–55,63,69,72,86,110,119,130,132,134] 17% (1) [25]
Other 1% (1) [94] 0% (0)
Synthesis of results
Quantitative 1% (1) [133] 33% (2) [25,135]
Qualitative 99% (108) [26–132,134] 67% (4) [136–139]
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Table 2 – Summary of the conclusions of model comparisons.
Pathogen Number of
comparison
studies
Mean number of
modeling studies
included
Main conclusions (as presented by authors of comparative
modeling studies)
Human
papillomavirus
27 16 • Cost-effective for girls (HICs and LMICs)
• Not cost-effective for boys with high coverage among girls (HICs)
• Variable cost-effectiveness results for boys with low coverage
among girls (o40%–50%)
Inﬂuenza virus 25 16 • Cost-effective for elderly and targeted high-risk groups other than
age in HICs (e.g., health care workers)
• Variable cost-effectiveness results for working adults and children
in HICs (generally cost-effective when taking into account work
loss)
• Lack of quality studies for MICs and no evidence for LICs (two
reviews)
• Methodology, perspective of analysis, model assumptions, and
study quality vary greatly
Pneumococcus 23 16 • Variable cost-effectiveness results for children in HICs and LMICs
(requires herd effects and limited serotype replacement to be cost-
effective), but two reviews concluded that the vaccine was cost-
effective in LMICs
• Cost-effective in elderly in HICs
• Variable cost-effectiveness results for adults and high-risk groups
(one review)
Varicella zoster virus
(varicella
vaccination)
10 17 • Cost-effective in HICs (and may be cost-saving) if potential impact
on herpes zoster is ignored
• Not cost-effective in HICs (possible QALY losses) if herpes zoster
shows large increases
• Cost-effective for health care workers
Hepatitis B virus 10 14 • Cost-effective in areas of low to high endemicity
• Variable cost-effectiveness results for routine vaccination in
countries with very low endemicity
• Targeted strategies are cost-effective in areas with very low
endemicity (one review)
Rotavirus 10 24 • Cost-effective in LMICs
• Variable cost-effectiveness results in HICs (requires herd effects
and lower price to be cost-effective)
Varicella zoster virus
(herpes zoster
vaccination)
6 12 • Cost-effective in elderly for speciﬁc age groups in HICs (variable
age groups provided: 60–75, 65–75, and 470-y- olds) (duration of
protection is a key parameter)
Bordetella pertussis 7 14 • Cost-effective in children in HICs
• Variable cost-effectiveness results for booster doses and
vaccination of adolescents and adults in HICs (depends on herd
immunity)
Hepatitis A virus 8 19 • Cost-effective in areas of low to high endemicity
• Variable cost-effectiveness results for routine vaccination in
countries with very low endemicity
• Targeted strategies are cost-effective in areas with very low
endemicity (one review)
Neisseria meningitidis 6 10 • Variable cost-effectiveness results for meningococcal group C
vaccines in HICs (cost-effective if herd effects or high prevalence)
• Vaccines cost-effective in the meningococcal belt in Africa (one
review)
• Conﬂicting results for mass vaccination during outbreaks
Measles and rubella
viruses
5 18 • Cost-effective for both vaccines
• More analyses for LMICs are required (one review)
Dengue virus 2 9 • Results not sufﬁcient to support country-level decisions
• More research required
HIC, high-income country; LIC, low-income country; LMIC, low- and middle-income country; MIC, middle-income country; QALY, quality-
adjusted life-year.
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results. Many comparative modeling studies concluded that
supplementary work was required to have a clear picture of the
cost-effectiveness of vaccination, particularly for LICs (e.g., inﬂu-
enza, dengue, measles, and rubella), given remaining uncertain-
ties in assumptions or limited number of studies. Finally, HPV,
inﬂuenza, and pneumococcal vaccines have been the objects of
more comparative modeling studies in HICs than the actual
number of mathematical models. We identiﬁed 27, 25, and 23
comparative modeling studies of HPV, inﬂuenza, and pneumo-
coccal vaccination, respectively, and for each of these pathogens,
there is a mean of 16 mathematical modeling studies included in
the comparative modeling studies (Table 2).
Discussion
Our systematic review indicates that 95% of comparative model-
ing studies performed in the ﬁeld of vaccination were based on
previously published results without incorporating new harmon-
ized assumptions to increase comparability of the models. These
comparative modeling studies used a combination of systematic
and nonsystematic approaches to identify eligible studies. The
main outcome examined was the cost-effectiveness/cost-beneﬁt
of vaccination, and a qualitative synthesis of results was most
often presented. The remaining 5% of comparative modeling
studies identiﬁed were based on results from new simulations.
These studies used a nonsystematic approach to identify eligible
studies (mostly convenience samples); effectiveness and cost-
effectiveness/cost-beneﬁt of vaccination were both examined,
and qualitative and quantitative synthesis of results were pre-
sented. Comparative modeling studies made it possible to iden-
tify cost-effective vaccination strategies for 13 of the 14
pathogens examined.
Most comparative modeling studies in the ﬁeld of vaccination
were based on previously published results of cost-effectiveness.
This type of comparative modeling study has several advantages.
First, it is relatively inexpensive and easy to conduct. Second, the
main outcome examined, that is, cost-effectiveness, is a measure
that is easy to identify and compare between studies. Third, it is
possible to use a systematic approach to identify eligible studies,
which minimizes potential reviewer selection biases. Neverthe-
less, this type of comparative modeling study also has important
limitations. First, a quantitative synthesis of results (e.g., meta-
analysis, pooling of results, and meta-regression) is likely to be
misleading because of the different vaccination strategies exam-
ined or outcomes/outputs. Furthermore, because it is not possible
to examine in detail and understand the impact of different
model parameters and assumptions, these comparative model-
ing studies lead to very broad conclusions. For example, com-
parative modeling studies of model-based estimates of the
effectiveness and cost-effectiveness of pneumococcal vaccina-
tion reported that cost-effectiveness results were variable for
vaccination of children in HICs as well as adults and high-risk
groups in all countries (the only consistently cost-effective
strategy was vaccination of elderly in HICs). These reviews high-
lighted that results from different studies likely depended on a
number of assumptions and methodological choices (e.g., includ-
ing existence of herd effects, costs considered, and vaccine
efﬁcacy), without speciﬁcally teasing out the speciﬁc driving
factors for the variability in conclusions.
Very few comparative modeling studies identiﬁed in our
systematic review were performed with new simulations, even
though this type of study has several strengths. First, because
these comparative modeling studies use standardized vaccina-
tion scenarios and outcomes/outputs, it is easier to perform
quantitative analyses and examine the impact of different model
parameters and/or structural assumptions. Such model
comparisons can also illustrate and examine parameter and
structural uncertainty. Averaging over model with different
structural assumptions has been proposed as one way to capture
this aspect of uncertainty [24]. For example, Brisson et al. [140],
with a group of 30 co-authors, recently conducted a comparative
modeling study on the population-level impact of girls-only HPV
vaccination combining data from 16 independent models. By
requesting standardized outputs for prespeciﬁed vaccination
scenarios, it was possible to conclude that HPV models were
generally consistent in their predictions of the direct and herd
effects of girls-only vaccination, even though models differed in
structure, settings, and data used for calibration. Furthermore, by
collecting detailed information on the models’ characteristics, it
was possible to perform a meta-regression, which identiﬁed three
main sources of heterogeneity between model predictions: the
predicted impact of HPV vaccination was higher when models did
not include risk groups for sexual activity, assumed lower natural
immunity among women, and/or included the natural history of
cervical cancer. Another example is the comparative modeling
study by Penny et al. [25]. The authors performed harmonized
comparisons of the effectiveness and cost-effectiveness of the
RTS,S/AS01 malaria vaccine using four different models.
Although there were differences in the four models, they reached
consensus about the predicted effectiveness and cost-effective-
ness of vaccination in children aged 6 to 9 months. Furthermore,
this work made it possible to understand the impact of the main
differences between the models (e.g., baseline parasite preva-
lence, assumptions about rates of immune acquisition, and
immunity). Nevertheless, comparative modeling studies using
new simulations also have limitations. Most of these compara-
tive modeling studies used a nonsystematic procedure to identify
studies and are consequently more likely to be affected by
reviewer selection bias. In addition, comparative modeling stud-
ies with new simulations are time-consuming, costly, require the
collaboration of many modeling teams, and usually require
funding for the extra simulations to be conducted. Finally, it is
important to keep in mind that comparative modeling studies,
with or without the use of new simulations, are strongly depend-
ent on the quality of the models included. In this regard, there are
several recent and ongoing efforts to standardize mathematical
modeling studies [14,15] to increase their quality and compara-
bility. Adherence to these mathematical modeling guidelines
represents a ﬁrst step toward providing better tools for decision
making. Comparative modeling can then be used to help examine
whether lack of quality of some models may have affected their
results/conclusions in comparison with higher quality models
(i.e., those with greater ﬁdelity to guidelines). In addition, even
though mathematical modeling guidelines can help ensure com-
parability between models, there are still structural assumptions
in the models that cannot be standardized because they repre-
sent uncertainly about the underlying features of the disease/
intervention and the best way to represent them mathematically.
Hence, adequate comparative modeling, conducted according to
standardized guidelines, can help explore the impact of these
assumptions.
Conclusions
To our knowledge, this is the ﬁrst systematic review to identify
and examine comparative modeling studies of the effectiveness
and cost-effectiveness of vaccination. We identiﬁed 115 different
comparative modeling studies examining the effectiveness and
cost-effectiveness of vaccination against 14 pathogens. Our
results show a steep rise in comparative modeling studies
examining the effectiveness and cost-effectiveness of vaccina-
tion, which is in line with the exponential rise in original
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modeling studies and the demand for such analyses to help
policy decisions. Nevertheless, contrary to other methods of data
synthesis, such as systematic reviews and meta-analysis of
empirical studies, there are no clear guidelines of how to conduct
comparative modeling studies. Guidelines are thus required for
comparative modeling studies to enhance their quality and
transparency and to ultimately provide better tools for decision
making.
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